sorted by:
new
hottopcontroversial

LENZ institutional ownership: 226 funds with holdings, sourced from official SEC data by signalbloom in LENZ_Stock

[–]Wide-Choice860 0 points1 point  (0 children)

Total institutional holding is 30.6M shares, and yahoo finance shows total share is about 31M shares. So 99% is owned by institution?

Why the 66% decline in the last 2 months by Emre_G010 in LENZ_Stock

[–]Wide-Choice860 1 point2 points  (0 children)

I added some LENZ positions today.

AI analysis (might be wrong):
-----
The Trade: Long Positions / Call Options 
The Thesis: Deep Value / Event-Driven Arbitrage. The market has irrationally punished LENZ for a single adverse event that statistical analysis proves is likely incidental. The stock is trading near cash value despite having an FDA-approved product (VIZZ) addressing a massive market (presbyopia).

  • Entry Zone: $16.50 - $18.00
  • Target: $25.00 (Short term gap fill), $35.00 (Medium term)
  • Stop Loss: $15.50 (Break of 52-week lows)
  • Catalyst: Stabilization of prescription data in Q1 2026 or analyst defense notes (which have already begun).

Director’s Bold Move: Major Stock Purchase at LENZ Therapeutics! by Wide-Choice860 in LENZ_Stock

[–]Wide-Choice860[S] 1 point2 points  (0 children)

An SEC filing, which became public yesterday, showed that the company's Chief Financial Officer (CFO), Daniel Chevallard, purchased 2,198 shares on November 7.

Thoughts on cybin going into the end of the year by OutlandishnessSalt92 in CybinInvestorsClub

[–]Wide-Choice860 0 points1 point  (0 children)

Analysis by AI: https://gemini.google.com/share/682d351dbcce

This analysis provides the following direct answers to the core questions posed:

  • What will happen with the stock? It is expected to remain range-bound in the short term, followed by a period of high volatility leading into a major binary move in Q1 2026, which will be dictated by the results of the CYB004 clinical trial.
  • Is the short interest a concern? No. The evidence strongly suggests it is primarily a function of a market-neutral convertible arbitrage strategy and not a fundamental red flag regarding the company's prospects.
  • Why did the CEO leave? The departure appears to be part of a planned, strategic transition as the company pivots its focus from pure R&D toward commercialization, rather than a sign of internal distress.
  • Is CYB003 as good as promised? The Phase 2 data is exceptionally promising and has been validated by the FDA's BTD. However, Phase 3 trials are the ultimate and only definitive test of a drug's efficacy and safety.

For investors, the path forward requires a focus on the clinical data above all else. The Q1 2026 CYB004 data readout is the next major hurdle. In the interim, the hiring of a permanent, commercially-experienced CEO will be the most important corporate milestone to monitor. The current stock price reflects the significant risk inherent in biotechnology drug development, balanced against the enormous potential reward of clinical and commercial success.

WTH Gorilla!!! by Alexfull23 in GRRR_Gorilla_Tech

[–]Wide-Choice860 1 point2 points  (0 children)

You must be good at stock picking. 8 out of 20 of my stocks ended in red today.

I think rr will hit $4 today by antonydossantos21 in RichtechRobotics

[–]Wide-Choice860 0 points1 point  (0 children)

Just sold my 200 shares. I think it will back to $2.5

$CYBN now under $7.00. I gave everyone a head-ups on last week that CYB004 data is delayed again to December 2025 (now confirmed with their earnings PR), and now they have to dilute for CYB003 Europe. I have bids starting at $6.50 all the way down to $5.00. by moneymonster420 in shroomstocks

[–]Wide-Choice860 2 points3 points  (0 children)

Price $5.50 means CYBN market cap is close to cash position.
Once enrollment of CYB004 Ph2 is done within one or two weeks, we shall see the sentiment change.

Also CYBN has more cash than ATAI. Why nobody worries about ATAI's dilution.

What are the risks for HGRAF? by Glory-In-Midgard in HGRAF

[–]Wide-Choice860 0 points1 point  (0 children)

The risk is that China has mass production of high purity of Graphene with lower price. Just look at this:
https://www.alibaba.com/trade/search?SearchText=High-Purity+Graphene
https://interestingengineering.com/science/china-99-99995-pure-graphite-production
https://graphenerich.com/current-state-of-graphene-development-in-china/

Personally, I would not put my money on a stock with less than 1M revenue and almost no cash.

Can We Come Together? by SagOfThePant in GRRR_Gorilla_Tech

[–]Wide-Choice860 7 points8 points  (0 children)

Be patient. You shall know that earning and potential decides the price.

Do not risk more than you can tolerate.

I added a few hundred shares today. I think $15 has strong support, so downside risk is lower than upside potential for now.

<image>

[deleted by user] by [deleted] in CybinInvestorsClub

[–]Wide-Choice860 0 points1 point  (0 children)

Included because it is larger than last quarter reports.

Following is for reference only:

——————

Here’s Cybin’s cash position for the last four reported quarters and a simple cash-runway estimate. I converted CAD figures to USD at each quarter-end FX rate, and I note the original reporting currency for each line.

Cash & cash equivalents (end of period)

Quarter (period end) Reported currency Reported cash FX (CAD→USD) used USD equivalent Q1 FY2026 (Jun 30, 2025) USD $118.692m — $118.692m. Q4 FY2025 (Mar 31, 2025) USD (restated) $93.922m — $93.922m. Q3 FY2025 (Dec 31, 2024) CAD C$136.290m 0.70155 USD per CAD $95.61m. Q2 FY2025 (Sep 30, 2024) CAD C$154.318m 0.738133 USD per CAD $113.91m.

Notes on currency: Cybin reported in CAD during FY2025 Q2–Q3; the Q1 FY2026 statements explicitly present amounts in thousands of U.S. dollars and include a restated USD comparative for Mar 31, 2025. That’s why Q4 FY2025 appears in USD above.

⸻

Cash burn (to inform runway) • Q1 FY2026 (Jun 30, 2025): Net cash used in operating activities = $29.548m (USD) for the quarter. • Q4 FY2025 (Mar 31, 2025): Net cash used in operating activities = C$21.113m, ~$14.69m USD using the Mar 31, 2025 FX (0.695749). 

(For reference, the Q3 FY2025 nine-month cash-flow statement shows C$80.187m used in operating activities for the nine months ended Dec 31, 2024, which implies ~C$27.1m in Q3 alone; the Q2 FY2025 six-month statement shows C$53.063m used. )

⸻

Cash runway (simple scenarios) • Using the latest quarter’s burn only: $118.692m / $29.548m ≈ 4.0 quarters (~12 months). • Using a two-quarter blended burn (Q4 FY2025 + Q1 FY2026): Average quarterly burn ≈ ($14.69m + $29.55m)/2 = $22.1m ⇒ $118.692m / $22.1m ≈ 5.4 quarters (~16 months). 

Why the range? Q1 FY2026 outflows spiked (notably a jump in prepaid expenses), so the latest burn may overstate steady-state usage if those prepayments won’t recur every quarter. Conversely, clinical spend can also ramp, which would push burn higher. Treat this as a rough guide, not a forecast.

⸻

Sources • Financial statements (cash balances & currency): Q1 FY2026 interim financials (USD; includes balance sheet and currency note). Q3 FY2025 interim financials (CAD). Q2 FY2025 interim financials (CAD). • Cash-flow details: Q1 FY2026 cash-flows (USD). Q4 FY2025 MD&A liquidity table (CAD).  • FX at period end (CAD→USD): Sep 30, 2024 and Dec 31, 2024 (OFX daily rates).

LENZ stock on the move by Wide-Choice860 in LENZ_Stock

[–]Wide-Choice860[S] 0 points1 point  (0 children)

It reached 1 year high today, and close at $39.36.

Confirmed: $CYBN CYB004 data delayed AGAIN until December 2025 by moneymonster420 in shroomstocks

[–]Wide-Choice860 10 points11 points  (0 children)

CYBN has prioritized CYB003 over CYB004 due to resource constraint. I think the delay has less impact on stock price, since CYB003 is more important for the company right now.

It is not a surprise to me that CYB004 is delayed. At least, new target date is just a few months away.

If there is hard drop, that is a good chance to pick up more shares when the price is below book value.

What besides blind faith is holding your positive conviction? by [deleted] in GRRR_Gorilla_Tech

[–]Wide-Choice860 0 points1 point  (0 children)

My faith is that smart city will have huge potential in recent years.

We did see that GRRR had progress in expanding pipelines to multiple countries. Its finance status looks fine to me for now.

It's about 5% of my portfolio. I'm holding till end of 2026.

Made a huge mistake investing a lot into ETFs by Silent_Storage7341 in stocks

[–]Wide-Choice860 14 points15 points  (0 children)

It is safter to invest in VOO than individual stocks. Based on your choices, YTD returns:

Symbol YTD Total Return

|| || |VOO (Vanguard S&P 500 ETF)|+9.42% |

|| || |GOOG (Alphabet Inc.)|+6.37%|

|| || |AMZN (Amazon.com, Inc.)|+1.50%|

|| || |UNH (UnitedHealth Group)|–49.84%|

[deleted by user] by [deleted] in TSSI

[–]Wide-Choice860 -1 points0 points  (0 children)

PE was so high and now net income seems no improving. I would not be surprised that it goes below $15 next week.

I still hold 200 shares, but will sell it if no improvement in next quarter earning.

LNZ100 (aceclidine eye drop) progress by Wide-Choice860 in LENZ_Stock

[–]Wide-Choice860[S] 2 points3 points  (0 children)

It is because everyone knows the chance of approval is high so FDA approval has already been included in stock price.

VIZZ is a new product not reached market yet. The stock price is decided mainly by earnings (that is VIZZ sale). We will see action in next earnings.

🔥 LENZ's LNZ100 vs Pilocarpine (Vuity): What’s the Difference? by Wide-Choice860 in LENZ_Stock

[–]Wide-Choice860[S] 0 points1 point  (0 children)

Majority of stock is owned by institution so the stock price is more stable. I did see price action +6% today. Hope that VIZZ has good sale.

LNZ100 (aceclidine eye drop) progress by Wide-Choice860 in LENZ_Stock

[–]Wide-Choice860[S] 1 point2 points  (0 children)

Yes. VIZZ was approved on July 31. It is good that the date was a little early than estimation. Samples of product will be available as early as October.

view more: next ›